TERN - Terns Pharmaceuticals, Inc. Stock Price, Fair Value and News

$6.89+0.01 (+0.15%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TERN Price Action

Last 7 days

-8.3%

Last 30 days

-19.5%

Last 90 days

-11.2%

Trailing 12 Months

29.3%

TERN RSI Chart

TERN Valuation

Market Cap

484.2M

Price/Earnings (Trailing)

-5.05

Price/Sales (Trailing)

39.87

EV/EBITDA

-4.12

Price/Free Cashflow

-6.12

TERN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TERN Fundamentals

TERN Revenue

Revenue (TTM)

12.9M

Rev. Growth (Yr)

-15.29%

Rev. Growth (Qtr)

-9.62%

TERN Earnings

Earnings (TTM)

-95.9M

Earnings Growth (Yr)

-27.05%

Earnings Growth (Qtr)

-1.62%

TERN Profitability

EBT Margin

-741.26%

Return on Equity

-43.85%

Return on Assets

-41.53%

Free Cashflow Yield

-16.33%

TERN Investor Care

Shares Dilution (1Y)

15.23%

Diluted EPS (TTM)

-1.32

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	4.7M	7.9M	0	12.9M
2022	228.0K	387.0K	837.0K	2.1M
2021	0	118.0K	117.0K	170.0K
2020	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

WEBSITE	ternspharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	46

Terns Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Terns Pharmaceuticals, Inc.? What does TERN stand for in stocks?

TERN is the stock ticker symbol of Terns Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Terns Pharmaceuticals, Inc. (TERN)?

As of Tue Oct 29 2024, market cap of Terns Pharmaceuticals, Inc. is 484.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TERN stock?

You can check TERN's fair value in chart for subscribers.

Is Terns Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether TERN is over valued or under valued. Whether Terns Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Terns Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TERN.

What is Terns Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 29 2024, TERN's PE ratio (Price to Earnings) is -5.05 and Price to Sales (PS) ratio is 39.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TERN PE ratio will change depending on the future growth rate expectations of investors.